8-K: Bellevue Life Sciences Secures $800,000 Loan with Potential Equity Conversion

Bellevue Life Sciences Acquisition Corp. has entered into an agreement for an $800,000 loan that may convert to equity upon a future financing event.

Summary

• Bellevue Life Sciences Acquisition Corp. has received an $800,000 unsecured loan from Duksung Co., LTD.
• The loan, referred to as the Duksung Promissory Note, carries a 5% annual interest rate, which increases to 7% for prepayment purposes.
• The loan matures on October 15, 2025, unless converted earlier.
• The note will automatically convert into company common stock if a 'Qualified PIPE Financing' occurs, at a conversion price of $8.10 per share.
• A 'Qualified PIPE Financing' is defined as a private financing of at least $1,500,000, excluding the proceeds of this note, that occurs before or at the same time as the company's business combination with OSR Holdings Co., Ltd.
• If a Qualified PIPE Financing does not occur by March 31, 2025, the company can prepay the loan at the 7% interest rate.

Sentiment

Score: 6

Explanation: The document indicates a neutral to slightly positive sentiment. The company has secured funding, but there are risks associated with the debt and the need for a future financing event. The terms are fairly standard for this type of agreement.

Positives

• The company has secured additional funding of $800,000.
• The loan has a potential conversion to equity, which could reduce debt obligations.
• The loan provides flexibility with a prepayment option if the PIPE financing does not occur by the specified date.

Negatives

• The loan carries an interest rate, which will increase the company's expenses.
• The company is obligated to repay the loan if a Qualified PIPE Financing does not occur by March 31, 2025.
• The conversion price of $8.10 per share may be dilutive to existing shareholders if the conversion occurs.

Risks

• The company may need to repay the loan if a Qualified PIPE Financing does not occur by March 31, 2025.
• The conversion of the loan to equity could dilute existing shareholders.
• The company's ability to secure a Qualified PIPE Financing is uncertain.

Future Outlook

The company's future financial structure is dependent on whether a Qualified PIPE Financing occurs, which would convert the debt to equity. If not, the company will need to repay the loan by October 15, 2025, or earlier if they choose to prepay after March 31, 2025.

Management Comments

• The company has not provided any direct quotes in this document.

Industry Context

This type of financing is common for companies, especially those in the life sciences sector, seeking to bridge funding gaps before a larger capital raise or business combination. The convertible note structure is often used to attract investors with the potential for equity upside.

Comparison to Industry Standards

• Convertible notes are a common financing tool for pre-revenue or early-stage companies, particularly in the biotech and life sciences sectors.
• The interest rates of 5% and 7% are within the typical range for such notes, although the specific rate depends on the risk profile of the company and the market conditions.
• The conversion price of $8.10 per share is specific to this company and its valuation at the time of the agreement.
• The $1.5 million minimum for a qualified PIPE financing is a common threshold to ensure a meaningful capital raise.

Stakeholder Impact

• Shareholders may experience dilution if the note converts to equity.
• Creditors are impacted by the terms of the loan and the potential for repayment or conversion.
• The company's financial stability is affected by the debt and the need for a future financing event.

Next Steps

• The company needs to secure a Qualified PIPE Financing before March 31, 2025, to trigger the conversion of the note to equity.
• If a Qualified PIPE Financing does not occur, the company will need to prepare for repayment of the loan by October 15, 2025, or earlier if they choose to prepay after March 31, 2025.

Key Dates

Keywords

promissory note, convertible debt, PIPE financing, loan, equity conversion, Duksung Co., LTD., Bellevue Life Sciences, funding